Supernus Pharmaceuticals (SUPN) Change in Receivables (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Change in Receivables data on file, last reported at -$5.6 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at -$5.6 million, down 257.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (up 726.65% YoY), and the FY2025 annual result was $22.3 million, up 1173.34% from the prior year.
• Change in Receivables declined to -$5.6 million in Q1 2026 per SUPN's latest filing, from $16.4 million in the prior quarter.
• Over five years, Change in Receivables peaked at $16.4 million in Q4 2025 and troughed at -$22.0 million in Q1 2023.
• A 5-year average of $718117.6 and a median of $2.4 million in 2023 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2023 and 2025: Change in Receivables plunged 476.36% in 2023, then jumped 592.92% in 2025.
• A 5-year view of Change in Receivables shows it stood at $1.4 million in 2022, then soared by 69.74% to $2.4 million in 2023, then slumped by 239.37% to -$3.3 million in 2024, then jumped by 592.92% to $16.4 million in 2025, then tumbled by 134.22% to -$5.6 million in 2026.
• Business Quant data shows SUPN's Change in Receivables at -$5.6 million in Q1 2026, $16.4 million in Q4 2025, and $7.1 million in Q3 2025.